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The analysis of 2-amino-2-thiazoline-4-carboxylic acid in
the plasma of smokers and non-smokers
Brian A. Logue1, Wendy K. Maserek1, Gary A. Rockwood2, Michael W. Keebaugh2 and
Steven I. Baskin2
1
2

Department of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota, USA
US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland, USA

Abstract
ATCA (2-amino-2-thiazoline-4-carboxylic acid) is a promising marker to assess cyanide exposure because of
several advantages of ATCA analysis over direct determination of cyanide and alternative cyanide biomarkers (i.e. stability in biological matrices, consistent recovery, and relatively small endogenous concentrations).
Concentrations of ATCA in the plasma of smoking and non-smoking human volunteers were analyzed using gaschromatography mass-spectrometry to establish the feasibility of using ATCA as a marker for cyanide exposure.
The levels of ATCA in plasma of smoking volunteers, 17.2 ng/ml, were found to be significantly (p < 0.001) higher
than that of non-smoking volunteers, 11.8 ng/ml. Comparison of ATCA concentrations of smokers relative to nonsmokers in both urine and plasma yielded relatively similar results. The concentration ratio of ATCA for smokers
versus non-smokers in plasma and urine was compared to similar literature studies of cyanide and thiocyanate,
and correlations are discussed. This study supports previous evidence that ATCA can be used to determine past
cyanide exposure and indicates that further studies should be pursued to validate the use of ATCA as a marker
of cyanide exposure.
Keywords: 2-amino-2-thiazoline-4-carboxylic acid, ATCA, Biomarker, Cyanide, Gas-chromatography
mass-spectrometry

Introduction
Verification of exposure to cyanide by analysis of biological matrices is important in the analysis of both accidental
exposure and deliberate release of cyanide. It is important
for forensic applications (i.e. analysis that relates to establishing evidence and does not affect medical treatment)
and diagnostic applications (i.e. analysis that establishes
the presence of a medical condition). There are two major
approaches used to verify cyanide exposure: (1) direct analysis of cyanide, and (2) analysis of the major cyanide metabolite, thiocyanate. Confirming cyanide exposure through
direct analysis is difficult due to the consumption of cyanide
in the daily diet, the volatility of hydrogen cyanide (HCN),

the nucleophilic properties of cyanide ion (CN−), and the
rapid metabolism of cyanide (half-life in plasma is reported
to be from 4 minutes to approximately 1 hour; Hartung 1982;
Lundquist et al. 1987; Baud et al. 1996; Baskin and Brewer
1997; Moariya and Hashimoto 2001).
Thiocyanate (SCN−) is the major product of cyanide
metabolism. The formation of thiocyanate occurs when
cyanide reacts with a sulfane sulfur donor (Isom and Baskin
1997), predominantly thiosulfate. This formation is enzymatically controlled by rhodanese (thiosulfate sulfurtransferase; Hebert 1993; Salkowski and Penney 1994 ; Tsuge
et al. 2000; Baskin et al. 2004). Although it is the major product of cyanide metabolism, difficulties have been noted in
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the use of thiocyanate for verification of cyanide exposure.
Thiocyanate is naturally found in biological fluids, and
while this is a condition of all cyanide biomarkers, normal
thiocyanate levels are very high and can be inconsistent
(Diem and Letner 1970; Pettigrew and Fell 1973; Jarvis 1989;
Maliszewski and Bass 1955; Yamanaka et al. 1991; Pre and
Vassey 1992; Tsuge et al. 2000; Hasuike et al. 2004). Large and
variable background thiocyanate concentrations (i.e. average SCN− concentrations are approximately 33.1 µM, 60 µM,
and 590 µM, for blood, urine, and saliva, respectively) make
it difficult to determine low-level cyanide exposure from this
metabolite. Ballantyne (1977) also found that concentrations
of thiocyanate in blood varied unpredictably during storage
at a number of temperatures and that analytical recovery of
thiocyanate from whole blood was inconsistent. Large and
variable concentrations may indicate that thiocyanate is
involved in a number of biological processes in addition to
cyanide metabolism. In fact, significant use of thiocyanate
by biological processes other than cyanide metabolism has
been established (Wood et al. 1947; Wood and Williams
1949; Isom and Baskin 1997).
An alternative approach to verification of cyanide
exposure is to analyze biological matricies for 2-aminothiazoline-4-carboxylic acid (ATCA). The formation of
ATCA from cyanide, as shown in Figure 1, appears to be
an important biological pathway for cyanide detoxification (Salkowski and Penney 1994; Baskin and Brewer 1997;
Borowitz et al. 2001). When cyanide reacts with cystine,
ATCA or 2-iminothiazolidine-4-carboxylic acid (ITCA) is
formed. These two tautomers, ATCA and ITCA, may be in
equilibrium (Figure 1; Lundquist et al. 1995) and will be
referred to as only ATCA. Approximately 15% of the initial
dose of cyanide is converted to ATCA (Wood and Cooley
1956) by direct interaction of cyanide with cystine and not
from other processes.
In biological samples, ATCA is stable for months at various temperatures (Lundquist et al. 1995; Logue et al. 2005).
Relatively few techniques have been described to analyze
ATCA from biological matrices, including spectrophotometry
(Bradham et al. 1965; Baskin et al. 2006) and high-performance liquid chromatography (Lundquist et al. 1995). More
recently, Logue et al. (2005) described a gas-chromatography
mass-spectroscopic (GC-MS) method to analyze ATCA
in human urine and reported concentrations of ATCA in
smokers and non-smokers. Relatively few studies have been
performed to evaluate the relationship between ATCA and
cyanide, although recent studies have shed some light on this
issue. Elevated concentrations of ATCA in the urine of smokers compared to non-smokers have been found (smokers
inhale a small amount of cyanide while smoking; Lundquist
et al. 1995; Harris 1996; Logue et al. 2005) and it has been
established that ATCA is not metabolized further (Wood and
Cooley 1956; Weuffen et al. 1980; Baskin et al. 2004). ATCA is
excreted mainly in the urine (Baskin et al. 2004), and its toxicokinetics have not been specifically established. Although
there are no specific toxicokinetic studies of ATCA, previous
studies of the behavior of ATCA indicate that it has properties
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Figure 1. The production of ATCA from cyanide and cystine.

consistent with a lasting signature of cyanide exposure.
Besides being a marker of cyanide exposure, ATCA may play
a role in the neurotoxic effects of cyanide, as it appears to
have some level of neurotoxicity (Bitner et al. 1997).
The relationship between cyanide exposure and markers of
exposure must be understood in order to utilize a specific cyanide biomarker. If a strong relationship is established, forensic, clinical, military, scientific, and veterinary investigators
could use this marker for diagnostic or forensic confirmation
of cyanide exposure. The purpose of this study was to further
evaluate the potential of ATCA for use as a valuable marker
of cyanide exposure by evaluating the relationship between
cyanide inhalation and ATCA concentrations in the plasma of
smokers and non-smokers. These concentrations were compared to similar studies of ATCA, cyanide, and thiocyanate.

Materials and methods
Reagents
ATCA (full chemical name: L-2-amino-2-thiazoline4-carboxylic acid) was obtained from Chem-Impex
International (Wood Dale, IL). A standard stock solution
(100 g/mL) was prepared in 0.1 M HCl and used throughout the current study. Oasis solid-phase extraction (SPE)
columns were obtained from Waters Corporation (Milford,
MA). The derivatizing agent N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was purchased from Pierce
Chemical Company (Rockford, IL). The internal standard,
deutereated ATCA (ATCA-d2), was obtained from the lab
of Dr Herbert T. Nagasawa (Department of Veterans Affairs
Medical Center, Minneapolis, MN), prepared by reaction of
deuterated L-cysteine (3,3-d2) with cyanamide (Nagasawa
et al. 2004). HPLC grade solvents and reagents were used
throughout the study and were purchased from SigmaAldrich (St. Louis, MO).
Biological fluids
Plasma samples from human subjects, age 18–60, were
used to evaluate the applicability of the analytical method.
Six male subjects (three smokers and three non-smokers)
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donated samples of blood at 8:00 a.m. (designated ‘morning’), at noon, and at 5:00 p.m. (designated ‘afternoon’) on
three separate days over the course of a week (54 samples
total). The smoking individuals (as defined by individuals
who smoke at least five cigarettes per day with no other form
of tobacco use) represent low level chronic exposure to cyanide through cyanide inhalation. Accurate intake of cyanide
for individuals in this group is difficult to estimate because
of variation in the number of cigarettes smoked, the cyanide
dose per cigarette, the act of inhalation, etc. Therefore, these
individuals will be referred to only as ‘smokers’.
Whole-blood samples were collected (2 mL) and mixed
with EDTA. The samples were initially vortexed to ensure
complete mixing prior to separation of the plasma and red
blood cell fractions by centrifugation. The separate fractions were collected and stored in a freezer until analysis. To
determine the effect of time variation on plasma concentrations of ATCA, smoking and non-smoking volunteers were
separated into subgroups which were defined by days of
week and time of day (e.g. smokers on Friday afternoon).
Each subgroup was analyzed for significant difference (see
‘Calibration, quantification, and data analysis’ section). All
samples were gathered under approved human use protocols from the gathering institution.
Sample preparation
Samples were diluted 1:10 in 1 mL of 0.1 M HCl. Acidifying
the plasma matrix ensured the amine moiety on ATCA
(Figure 1) was protonated. Deuterated ATCA (100 L of
1000 ng/mL ATCA-d2) was added to the diluted sample as
an internal standard. After conditioning with successive
washes of 1 mL each of methanol and H2O, the diluted sample was aspirated through an SPE column. The column was
then washed successively with 1 mL each of 0.1 M HCl and
100% methanol. ATCA was then eluted into 2 mL microcentrifuge tubes using 29% (w/w) NH4OH. Because highly
basic solutions can chemically alter the ATCA structure, a
small amount of concentrated HCl (200 L) was added to
the centrifuge tube to decrease the solution pH. The solvent
was removed from the samples in a centrifugal evaporation
system at 70°C for at least 6 hours. Derivatization of the dried
samples was carried out at 50°C using 150 L of 30% MSTFA
in hexane for 1 hour in capped centrifuge tubes to produce
trimethylsilyl-derivatized ATCA (ATCA-(TMS)3).
Gas-chromatography mass-spectrometry
Analysis was performed on an Agilent GC-MS system consisting of a 6890 Series II gas chromatograph, a 5973N series
mass-selective detector, and a 7683 auto-sampler. The column used was a DB-5MS bonded phase column (30 m × 0.25
mm I.D., 0.25 m film thickness; J&W Scientific, Folsom, CA)
with helium as the carrier gas at a flow rate of 0.1 mL/min.
The GC oven temperature was initially held at 100°C for 1
minute, and then elevated at a rate of 15°C/min up to 250°C.
The gradient was then increased at a rate of 30°C/min up to
280°C and held constant for 1 minute. The GC was interfaced
with a mass-selective detector in selected ion monitoring

(SIM) mode for monitoring abundant ions of ATCA-(TMS)3
(m/z 245, 347, and 362) and ATCA-d2 (m/z 349 and 364) with
a dwell time of 100 ms each. Other parameters are reported
by Logue et al. (2005).
Calibration, quantification, and data analysis
Calibration samples were prepared in the range of 10–1000
ng/mL by diluting the stock ATCA solution in water as a
surrogate and adding 100 ng/mL ATCA-d2 as an internal
standard. Calibration was performed by plotting peak area
ratios of ATCA to internal standard (ATCA-d2) of individual
ions 362 and 364, respectively. The error involved in analyzing plasma samples for ATCA is reported in standard error of
the mean throughout the text. Alternatively, it is sometimes
useful to report the standard deviation of the data. For this
study, the standard deviation for the analysis of ATCA in
plasma was 5.2 ng/mL and 4.6 ng/mL for smokers and nonsmokers, respectively. Comparison of the plasma samples for
significant differences in the ATCA concentrations of smokers compared with non-smokers was accomplished using a
two-tailed t-test. Comparison of each sub-group of smokers
and non-smokers (e.g. non-smokers on Friday morning)
was accomplished by a two-way analysis of variance and the
Bonferroni multiple range test to identify significant differences between the identified subsets of volunteers.

Results and discussion
ATCA concentrations in smoker and non-smoker plasma
Human cyanide exposure can be evaluated directly
through analysis of biological matrices of smokers or
victims of accidental exposure (Chandra et al. 1980;
Lundquist et al. 1987; Harris 1996; Their et al. 2000; Tsuge
et al. 2000; Riddle 2004; Eckstein and Maniscalco 2006;
Geller et al. 2006; Scherer 2006). Cyanide concentrations
in the plasma, whole blood, saliva, and tissues of smokers are elevated with respect to non-smokers because a
small amount of cyanide intake occurs during the act of
smoking (Chandra et al. 1980; Lundquist et al. 1987; Harris
1996; Tsuge et al. 2000). There is also an inherent amount
of cyanide present in blood samples and other biological
tissue due to the consumption of various foods that contain cyanide and the breakdown of amino acids (Baskin
and Brewer 1997; Ellenhorn and Barceloux 1997; Jones
1998). A portion of this inherent cyanide will presumably
be converted to ATCA (Figure 1; Wood and Cooley 1956;
Weuffen et al. 1980; Salkowski and Penney 1994; Harris
1996; Borowitz et al. 2001; Baskin et al. 2004). Therefore, as
with cyanide and thiocyanate, there should be measurable
endogenous levels of ATCA in human biological samples.
In fact, endogenous concentrations of ATCA were found in
human urine samples, with smokers having elevated concentrations relative to non-smokers (Logue et al. 2005).
Therefore, ATCA concentrations for smokers should also
be elevated above background levels of ATCA found in
non-smoker plasma. A representative chromatograph
for the analysis of ATCA from the plasma of a smoker is
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presented in Figure 2. As with all cyanide markers, significant endogenous concentrations of ATCA dictates
that ‘normal’ background levels of ATCA for both smokers
and non-smokers must be known for each individual biological matrix. Background levels must be known so that
significantly elevated levels of ATCA, which may indicate
cyanide exposure, can be determined.
The concentration of ATCA in the plasma of smoking and non-smoking volunteers was evaluated to determine whether there was a significant increase in ATCA
70000
73

60000

si
316
S

50000

Abundance

N

si

ATCA-(TMS)3
MW = 362

N
o

347

si

o

40000

362

245
245

30000

316 347
50

20000

100

150

200

250

300

350

m /z

10000

0
8.0

8.2

8.4

8.6

8.8

Time (min)

Figure 2. GCMS chromatograph of derivatized ATCA (ATCA-(TMS)3) in
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Figure 3. ATCA concentrations in the plasma of smokers compared to
non-smokers (error bars indicate the standard error of the mean for each
group). The concentration of ATCA was found to be significantly elevated
in the plasma of smokers (p < 0.001).

concentrations of smokers relative to non-smokers and to
estimate background levels of ATCA in the plasma of smokers and non-smokers. The plasma concentration of ATCA
in the volunteers was 17.2 ± 1.0 ng/mL and 11.8 ± 0.88 ng/
mL for smokers and non-smokers, respectively (Figure 3).
Comparing these two averages with a two-tailed t-test indicates that a significant difference exists between these two
groups at a 99.9% (p < 0.001) confidence level.
Evaluation of time dependence of ATCA exposure
Plasma samples were gathered throughout each day and over
the course of a 1-week period. Overall, the ATCA concentration ranged from 7.03–14.6 ng/mL for non-smokers and
13.6–19.4 ng/mL for smokers throughout the various times
during the week (Table 1). Each sub-group (e.g. non-smokers
at Wednesday noon) was analyzed for significant difference.
Although the amount of cyanide intake for smokers and
non-smokers can vary throughout the day and the week, the
concentration of ATCA did not significantly change (ANOVA
analysis p-values ranged from 0.84–0.35; the Bonferroni test
also confirmed that there were no significant differences
between these groups). The lack of significant variation of
ATCA concentrations between the day of the week and the
time of day indicates that the ATCA concentrations are fairly
stable over time. This would not be expected if the distribution and depuration half-lives were short (i.e. 1–2 hours); the
ATCA concentration would increase throughout the day. If
the distribution and depuration half-life of ATCA are long
(i.e. multiple hours), fairly stable concentrations of ATCA
would be seen.
The concentrations of ATCA for each sub-group in Table 1
are consistently larger for smokers than for non-smokers.
Although all ATCA concentrations are larger for smokers, the
difference between smokers and non-smokers on Wednesday
morning is insignificant. This is most likely due to the limited
number of samples gathered for each sub-group (n = 3) and
the error involved in analyzing human plasma samples for
ATCA. This sub-group illustrates that, although tentative
conclusions can be made from these sub-groups, a more
extensive study should be completed to validate the data.
Comparison of ATCA concentrations in human biological
matrices
Direct comparison of urine and plasma is not possible, but
ATCA concentrations for smokers in both urine (Logue et al.
2005) and plasma (this study) matrices are significantly
higher relative to non-smokers (saliva concentrations of
ATCA have thus far not been analyzed for smokers and nonsmokers). ATCA concentrations in urine were 115 ± 13 ng/

Table 1. ATCA concentrations in the plasma of smokers and non-smokers during various times during a 1-week period. The error for each entry is
reported in standard error of the mean (n = 3 for each group).
Monday
Wednesday
Friday
Smokers (ng/mL)
Non-smokers (ng/mL)
Smokers (ng/mL) Non-smokers (ng/mL) Smokers (ng/mL) Non-smokers (ng/mL)
Morning
19.2 ± 0.9
12.5 ± 4.0
14.7 ± 3.5
14.6 ± 1.3
18.7 ± 2.4
14.2 ± 2.0
Noon
13.6 ± 3.1
7.03 ± 1.6
15.3 ± 2.9
13.1 ± 2.2
18.7 ± 2.3
11.7 ± 1.4
Afternoon
18.1 ± 2.4
11.0 ± 3.5
19.4 ± 6.7
9.96 ± 2.6
16.7 ± 2.4
12.4 ± 4.4
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cyanide or thiocyanate), as indicated in the figure. The number below each bar indicates the reference from which the ratio was calculated: CS indicates ‘current study’; 1. Logue et al. (2005); 2. Sano et al. (1989); 3. Lundquist et al. (1987); 4. Tsuge et al. (2000); 5. Lundquist et al. (1985); 6. Hasuike
et al. (2004); 7. Jarvis (1989); 8. Maliszewski and Bass (1955); 9. Pre and Vassey (1992); 10. Yamanaka et al. (1991). The ratios of cyanide biomarkers were
1.32–1.51 for ATCA, 1.44–2.56 for cyanide, and 1.56–6.74 for thiocyanate.

mL and 87 ± 12 ng/mL for male smokers and non-smokers,
respectively (standard error of the mean given; Logue et al.
(2005) reported standard deviations of 46 and 36 ng/mL for
male smokers and non-smokers, respectively) while plasma
concentrations were 17.2 ± 1.0 ng/mL and 11.8 ± 0.88 ng/mL
for smokers and non-smokers.
While comparison of absolute concentrations of cyanide
biomarkers in different biological matrices is not possible,
comparison of the ratio of smokers relative to non-smokers
is possible (e.g. SCN− concentration in smokers’ plasma/
SCN− concentration in non-smokers’ plasma). The ratios of
mean ATCA concentrations of smoker to non-smoker were
analyzed from both urine and plasma matrices (Logue
et al. 2005; current study; Figure 4). These ratios were also
compared to cyanide and thiocyanate ratios from similar
studies (Maliszewski and Bass 1955; Lundquist et al. 1985,
1987; Jarvis 1989; Sano et al. 1989; Yamanaka et al. 1991;
Pre and Vassey 1992; Tsuge et al. 2000; Hasuike et al. 2004)
in a number of matrices (blood/plasma, saliva, and urine;
presented in Figure 4). The ratios are strikingly similar for
ATCA between plasma and urine with a calculated ratio
of 1.51 and 1.32, respectively. The ATCA ratio is also similar to the cyanide ratio, which ranged from 1.44–2.56 for
other similar studies (Lundquist et al. 1985, 1987; Sano
et al. 1989; Tsuge et al. 2000; Hasuike et al. 2004). The similarity of the ratios between cyanide and ATCA provides
evidence that ATCA production may be exclusively, or at

least predominantly, from cyanide metabolism, and that
there may be a direct link between elevated ATCA concentrations and cyanide exposure. Although cyanide ratios
show some inconsistency (Figure 4), the range of these
ratios is relatively small considering the difficulties in cyanide analysis and that different analytical methods were
used to analyze cyanide in these studies. As opposed to
ATCA and cyanide ratios, the ratios of thiocyanate are very
inconsistent between studies (Maliszewski and Bass 1955;
Jarvis 1989; Yamanaka et al. 1991; Pre and Vassey 1992;
Tsuge et al. 2000; Hasuike et al. 2004) and even within the
same study for different biological matrices (Jarvis 1989;
Yamanaka et al. 1991). The thiocyanate ratio ranged from
1.56–6.74. The ratio of thiocyanate for most of the studies in
Figure 4 is larger than the ratio of ATCA or cyanide, which
is an advantage for analyzing thiocyanate. The inconsistency of the thiocyanate ratio may indicate that production
or depletion of thiocyanate by sources other than cyanide
metabolism may be occurring. The variability of the thiocyanate ratio may also be caused by fast kinetics of thiocyanate production and depletion, where biological matrices gathered at different times may have quite different
thiocyanate concentrations depending on the biological
process most relevant. Another explanation as to the variability of thiocyanate between biological matrices is the
highly variable tissue distribution of rhodanese (Himwich
and Saunders 1948; Baskin et al. 2004).
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Figure 4 indicates that thiocyanate may not be a good
marker of cyanide exposure because of highly variable
endogenous concentrations. Scherer (2006) has also suggested that thiocyanate is limited as a marker of cyanide
exposure. Comparing the ratios of ATCA and thiocyanate to
cyanide indicates that ATCA may be a better-suited marker
for determining cyanide exposure. It should be noted that
some similar studies were excluded from Figure 4 because
the high variability in the data was such that the difference
between smokers and non-smokers of the species analyzed
was insignificant. Consideration of excluded studies still
supported the conclusions reached from this treatment of
the data.
These results, along with previous studies evaluating
ATCA as a possible marker of cyanide exposure, continue to
provide evidence that ATCA can be utilized as a marker for
cyanide poisoning in forensic and possibly diagnostic applications. The current study may be useful in identifying nonsmoking individuals who may be chronically overexposed to
cyanide in occupations where cyanide is extensively utilized
(e.g. gold mining operations). Future work must evaluate
the behavior (i.e. formation, distribution, and excretion) of
ATCA during and after controlled cyanide exposures. A relationship should also be established between the dose of cyanide and the formation of ATCA. Overall, this study further
supports the use of ATCA as a marker of cyanide poisoning.
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